CARB-X receives $50m from UK & Gates; Session at BIO on antibiotic reimbursement; PLOS opens an AMR Channel; CDD-sponsored SAR webinar

Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list…

  • CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds, CARB-X has raised more than $500 million. And the money is being applied at a furious pace: from its launch 21 months ago on 28 July 2016, CARB-X has funded 36 companies!! Showing that the projects are moving swiftly and the portfolio is being actively managed, 33 are still being funded and 3 have reached a project endpoint.
  • Antibiotic economics at BIO: The anti-infective track at the BIO meeting shows sessions that cover bacteria, fungi, and viruses. Note in particular these two:
  • PLOS announced that it has collaborated with GARDP to launch an AMR channel. Described as a global forum for AMR research, the press release says that the channel will provide research, commentaries, blogs, news, and discussions that span science, research and development, public health, and policy.
  • CDD (Collaborative Drug Discovery) will host a webinar on at 11a EST on 26 June on “SAR data in Drug Discovery”. Andrew Leach (ChEMBL) and Evan Bolton (PubChem) will discuss drug discovery informatics and ways to use the freely available PubChem and ChEMBL SAR data. This webinar is not specifically focused on AMR but rather looks like a good broad tour of tools that make SAR information more accessible.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Path to UNGA 2024 as of 3 May 24 / Events on 14-15 May (DC, NYC)

Dear All, Well, ECCMID 2024 (Barcelona) has come and gone. I saw many of you there … but it’s always so busy … and the conference center was simply enormous! Could not keep up. But, it was great to get the sense that we’re back as a community … very good attendance. The one thing

R&D Implications: Global Burden Disease is 28% Infectious!

Dear All (with thanks to Erin Duffy for co-authoring and with a wonkish alert! Refresh your coffee!), In a fascinating follow-up to their 2022 paper on the global burden of antimicrobial resistance (20 Jan 2022 newsletter entitled “#AMRSOS! GRAM Report: ‘At Least 1.27m Deaths/Year Directly Attributable To AMR’”), the team at IHME (Institute for Health

OHE £40k Policy Innovation Prize: AMR, anyone?

Dear All, One of your alert co-readers (Abigail Herron) pointed out to me the currently open call for applications for the OHE (Office of Health Economics) Innovation Policy Prize, a biennial £40k prize seeking “to promote thought leadership and solution-based theories around the big questions affecting the future of our industry.” Intriguingly for the AMR community, their

WHO call for data on pre-clinical antifungal R&D projects

Dear All, As part of their long-running project to maintain a useful view of the global antibacterial and antifungal pipelines, WHO yesterday announced a call for data on pre-clinical antifungal R&D projects. The scope is anything from Lead Optimization to pre-IND. Here are the links you need: The WHO webpage describing the call for data

Scroll to Top